Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4Urogenital Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1Disease 1

Interventions

pembrolizumab 4Nivolumab 4fludarabine 3aldesleukin 3Ipilimumab 3Cyclophosphamide 3vedolizumab 2enfortumab vedotin 2darolutamide 2cabozantinib 2atezolizumab 2Specimen Handling 2Riluzole 2Prednisone 2Magnetic Resonance Spectroscopy 2LDP-02 2Infliximab 2Immunoglobulin G 2Fecal Microbiota Transplantation 2Disulfides 2CTLA-4 Antigen 2CT-P13 2Biopsy 2relatlimab 1prednylidene 1palbociclib 1olaparib 1gallium 68 PSMA-11 1deltacortene 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × (225)Ac-PSMA-617 × 1 year × Clear all
NCT04597411 2026-04-30

Study of 225Ac-PSMA-617 in Men With PSMA-positive Prostate Cancer

Endocyte

Phase 1 Active not recruiting
101 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡